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Summary Cytokeratins are polypeptides that constitute a subclass of intermediate filaments in epithelial cells. The aim of the present study
was to evaluate the clinical usefulness of the serum evaluation of M3/M21 in patients with ovarian cancer. This retrospective study comprises
75 patients suffering from ovarian cancer FIGO stages la-l1l. M3/M21 reached a sensitivity of 78%, a specificity of 85%, a PPV of 89% and a
NPV of 83% using a cut-off level of 45 U 1-'. Forty-four women developed recurrent disease after complete remission during the observation
period. M3/M21 showed lead time effects in 19 patients, ranging from 2 to 8 months (median 3.2 months). Elevated M3/M21 serum levels
before therapy were associated with a poor overall survival (log-rank test, P = 0.02). Considering these preliminary results, the value of
M3/M21 as a serum tumour marker, i.e. to evaluate the tumour burden, seems promising.
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Cytokeratins are polypeptides that constitute a subclass of inter-
mediate filaments in epithelial cells (Moll et al, 1982). Tumours
with a strong proliferative rate produce huge amounts of cytoker-
atins, mainly cytokeratins 8, 18 and 19. Cytokeratin fragments are
soluble in body fluids and can be used as indicators of tumour
activity (Gion et al, 1994; Sundstrom et al, 1994).
The serum tumour marker M3/M21 is based on monoclonal
antibodies against the epitopes M3 and M21 of cytokeratin 18.
This property supposedly leads to a high specificity in detecting
fragments of cytokeratin 18. In breast cancer patients, it has been
shown that M3/M21 is elevated in sera of tumour patients
compared with normal controls, that it reflects the tumour burden
and that it is increased before the detection of recurrent disease
(Tempfer et al, 1996). To the authors' knowledge, no data
concerning M3/M21 in ovarian cancer have been reported.
The aim ofthe present study was to evaluate the clinical useful-
ness of M3/M21 in patients with ovarian cancer, regarding the
correlation with tumour burden and the possible prognostic and
monitoring potentials ofthis serum tumour marker.
MATERIALS AND METHODS
This retrospective study includes serological examinations of 75
patients suffering from ovarian cancer FIGO stages Ia (n = 7), Ic
(n = 12), II (n = 29) and III (n = 27). Median age at the time of
diagnosis was 55.6 years (range 36-71 years). Histologically, 36
tumours were graded as serous adenocarcinoma, 27 as mucinous
adenocarcinoma, five as undifferentiated carcinoma, three as clear
cell carcinoma and four as other kinds of ovarian cancer. All
patients underwent hysterectomy, pelvic lymphadenectomy and
omentectomy. Patients with stages Ic to III and patients with clear
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cell carcinoma underwent a platinum-containing chemotherapy
regimen. All patients were followed up at 3-month intervals. The
range of follow-up was 8-52 months. Forty-four patients devel-
oped recurrent disease after primary therapy, with a median
disease-free interval of 21 months (range 4-32 months). Thirty-
five patients died ofthe disease.
In all patients, M3/M21 serum levels were evaluated in samples
taken before surgery and during follow-up visits at 3-month inter-
vals. During chemotherapy, serum samples were taken at the
beginning and at the end of each course. As patients with no
evidence of disease (NED) were found to show higher M3/M21
serum levels than normal controls, we defined the lead time as
being the time interval between a continuous rise of the marker
above the median M3/M21 serum level in NED patients for two or
more consecutive evaluations and radiological or clinical evidence
of recurrent disease. Serum levels of M3/M21 were additionally
evaluated in a panel of 50 healthy blood donors and 15 patients
with benign inflammatory diseases ofthe pelvis.
Serum assay
Serum concentrations of M3/M21 were measured using the
M3/M21 IRMA (Beki Diagnostics AB, Bromma, Sweden), a two-
site radiometric immunoassay with the configuration that both the
catching antibody (mouse monoclonal M3) and the detection anti-
body (mouse antibody M21) are two separate and not overlapping
monoclonal antibodies directed against a soluble fragment of
cytokeratin 18. The intra-assay coefficient ofcorrelation was 5.1%
at a concentration of 35 U 1-'. All tests were run in duplicate
according to manufacturer's instructions.
Statistics
Comparisons between unpaired groups were made using the
Mann-Whitney U-test. Survival probabilities were calculated by
the product limit method ofKaplan and Meier. Univariate analysis
was assessed using the log-rank test. Chi-square test was used
where appropriate. P < 0.05 was considered to be statistically
significant.
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Figure 1 Receiver operator characteristics (ROC) curve for serum M3/M21,
using serial cut-off points ranging from 0 to 400 U 1-1
RESULTS
We evaluated M3/M21 serum levels in a panel of 50 apparently
healthy blood donors. A cut-off level of 45 U 1-1 was selected
according to the 95th percentile ofserum concentrations measured
in the panel of healthy controls. Median serum levels of M3/M21
in patients with ovarian cancer and in normal controls were 111.5
(minimum 24.6, maximum 1393.5) U ml-' and 21.0 (minimum 0,
maximum 52.1) U ml-1 respectively (Mann-Whitney U-test,
P = 0.0001). Furthermore, we evaluated M3/M21 serum levels in
15 patients with benign inflammatory disease of the pelvis. The
median serum level in these patients was 17.5 (minimum 0,
maximum 44.9) U ml-1 and did not differ from normal controls
(Mann-Whitney U-test, P = 0.3).
During the follow-up, median serum levels of M3/M21 in
patients suffering from recurrent disease and in patients with no
evidence ofdisease (NED) were 102.8 (minimum 32.2, maximum
967.4) U ml-1 and 66.1 (minimum 24.6, maximum 123.2) U ml-1
respectively (Mann-Whitney U-test, P = 0.004).
Using sera from healthy controls and sera from ovarian cancer
patients, taken before therapy, we calculated a receiver operator
characteristics curve using serial cut-off points ranging from 0 to
400 U 1-1, as shown in Figure 1. M3/M21 reached a sensitivity of
78%, a specificity of 85%, a PPV of 89% and a NPV of 83%
using a cut-off level of45 U 1-1. Evaluating M3/M21 serum levels
during the follow-up, sensitivity, specificity, PPV and NPV were
80%, 66%, 71% and 93% respectively. Elevated serum levels
of M3/M21 due to lead time effects were excluded from the
calculation.
Forty-four women developed recurrent disease after complete
remission during the observation period. M3/M21 showed lead
time effects in 19 patients, ranging from 2 to 8 months (median 3.2
months). Before therapy, serum M3/M21 was elevated above the
cut-off level in 39 patients. Lead time effects of M3/M21 were
only seen in cases with elevated M3/M21 serum levels before
therapy. In all patients displaying lead time effects, serum marker
levels of M3/M21 showed a consistent increase above the median
serum level ofNEDpatients. Patients responding to systemic treat-
ment (complete remission or partial remission as diagnosed by
computerized tomography) showed a decrease of M3/M21 serum
levels, except for seven patients, two ofwhom were later shown to
have progressive disease by computerized tomography. Patients
who did not respond to systemic treatment (steady disease or
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Figure 2 Kaplan-Meier analysis regarding overall survival of patients with
M3/M21 serum levels above the cut-off level (45 U 1-1) compared with
patients with M3/M21 serum levels below the cut-off level (45 U I-')
progressive disease as diagnosed by computerized tomography)
showed an increase ofM3/M21 serum levels in 30% of cases.
In our patient sample, CA 125 showed a sensitivity of 79%,
specificity of 91%, PPV of 69% and NPV of 92%. A lead time
effect of CA 125 was seen in 27 of 42 patients with a mean lead
time of3.8 months. Seven of 19 patients showing alead time effect
of M3/M21 did not have elevated CA 125 serum levels, therefore
in these cases M3/M21 could provide additional information
regarding early detection ofrecurrent disease.
When serum levels of M3/M21, taken before therapy, were
grouped by tumour stage, lymph node involvement, histological
type and histological grading, we found a statistically significant
correlation with histological grading. In patients with well-differ-
entiated tumour cells and moderately or undifferentiated tumour
cells, median serum levels of M3/M21 were 55.7 (minimum 35.9,
maximum 84.5) U 1-' and 421.5 (minimum 62.5, maximum
1393.5) U 1-1 respectively (Mann-Whitney U-test, P = 0.04). The
other investigated prognosticators showed no correlation with
M3/M21 serum levels.
Using the product limit method ofKaplan and Meier, we calcu-
lated the probability of pretreatment M3/M21 serum levels to
predict the overall survival. Elevated M3/M21 serum levels before
therapy were associated with a poor overall survival (log-rank test,
P = 0.02, Figure 2).
DISCUSSION
With a sensitivity of78%, a specificity of85%, a PPV of 89% and
a NPV of 83% M3/M21 is not suitable as a screening marker
for ovarian cancer. Given the low prevalence of the disease
(50: 100 000), this test would yield only 1 in 305 women with a
positive test actually having the disease.
Although M3/M21 is not suitable for ovarian cancer screening,
our data indicate that serum levels of M3/M21 evaluated before
therapy are predictive of the patient's outcome. Elevated M3/M21
serum levels were associated with a poor overall survival.
Multivariate analysis involving a bigger series of patients should
be performed to determine whether M3/M21 is an independent
prognostic factor in ovarian cancer.
Furthermore, M3/M21 evaluation seems to be useful for moni-
toring NED patients during follow-up. M3/M21 showed lead time
effects in 19 of44 patients with recurrent disease. Reports dealing
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with chemotherapy regimens in recurrent ovarian cancer have indi-
cated that early detection and onset of treatment results in a
prolonged survival (Thigpen et al, 1993). However, it has to be
noted that the PPV ofM3/M21 is considerably lowered during the
follow-up. We found a decrease of the PPV from 89% before
therapy to 71% during follow-up. This fact may be as a result of
the high M3/M21 serum levels in NED patients, which were found
to be higher than in normal controls. A low PPV leads to an
increase offalse-positive testresults, causing anxiety in the patient
and unnecessary diagnostic examinations. Therefore, a cut-off
with regard to the 95th percentile of serum concentrations
measured in NED patients (80 U 1-l) shouldbe used during follow-
up. A cut-off value of 80 U 1-' would yield a higher specificity
(89%) and PPV (93%), while essentially preserving a high sensi-
tivity of 74%. Furthermore, the combination of M3/M21 with
other serum markers should increase the diagnostic specificity and
the PPV. Different combinations with established serum markers
should be evaluated in further studies.
It has to be noted that elevated M3/M21 serum levels have to be
interpreted with caution as itis known that othermalignancies, e.g.
breast cancer, are also associated with elevated M3/M21 serum
levels (Tempfer et al, 1996). Our data indicate that inflammatory
conditions of the pelvis do not lead to false-positive M3/M21
elevations. However, it is known from other cytokeratin markers
that benign disorders, such as inflammatory disease of the liver,
are associated with elevated cytokeratin serum levels (Sabbatini
et al, 1988). This has to be taken into account when interpreting
elevated M3/M21 serum levels.
In the present study, we found significantly lower M3/M21
serum levels in patients with GI tumours compared with G2 and
G3 tumours, whereas M3/M21 serum levels were not associated
with tumour stage. This finding supports the assumption that
serum levels of cytokeratins are not reflective of the tumour bulk,
but rather indicative of strongly proliferating tumours (Bormer et
al, 1994; Devine et al, 1994).
In summary, our data indicate that in ovarian cancer patients
serum levels of M3/M21 are elevated in 78% of preoperative
serum samples, are significantly associated with the presence of
tumour, show good sensitivity/specificity characteristics and
display lead time effects during follow-up. Considering these
preliminary results, the value ofM3/M21 as a tumour marker, i.e.
to evaluate the tumour burden, seems promising. Additional
studies with an increased number ofpatients arejustified to clarify
further the prognostic value and the monitoring abilities of
M3/M21 in ovarian cancer patients.
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